James O'Callaghan1, Holly Holmes1, Nicholas Powell1, Jack Wells1, Ozama Ismail1, Ian Harrison1, Bernard Siow1, Michael O'Neill2, Emily Catherine Collins3, Karin Shmueli4, and Mark Lythgoe1
1Centre for Advanced Biomedical Imaging, University College London, London, United Kingdom, 2Eli Lilly & Co. Ltd, Surrey, United Kingdom, 3Eli Lilly and Company, Indianapolis, IN, United States, 4Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom
Synopsis
In this work, quantitative susceptibility mapping (QSM) and
T2* mapping were used to investigate iron accumulation both in-vivo and ex-vivo in a
mouse model of Alzheimer's Disease exhibiting tau pathology for the first time. Magnetic susceptibility increases relative to
controls were identified in grey matter and white matter brain regions and may
indicate sensitivity to tissue iron content. QSM in this mouse model may therefore provide
a non invasive method by which to dissect the relationship between iron and tau
pathology in Alzheimer's Disease.Purpose
The
storage of iron in the brain is disrupted in Alzheimer’s Disease (AD) where
deposition occurs in excess of the global increases associated with healthy
ageing[1].
Quantitative susceptibility mapping (QSM) is an emerging MRI technique
sensitive to iron concentration in tissue, that has recently displayed
comparable sensitivity to that of structural MRI as a biomarker of AD[2].
The ability to spatially map iron stores
in-vivo in mouse models of AD may provide a method by which to
interrogate their relationship with specific pathological traits. Despite evidence linking iron with tau
aggregation and neurofibrillary tangles, studies using MRI as a method of
in-vivo iron estimation have focussed on
mouse models of AD that develop beta-amyloid pathology[3].
In this work, a QSM protocol was used to probe tissue iron content in
the rTg4510, a transgenic mouse model that exhibits selective tau pathology. High resolution
ex-vivo data was acquired in the same cohort to support
in-vivo findings. Additionally, T2* mapping was performed to
compare QSM measurements with this more established MRI method of
in-vivo iron mapping[4].
Methods
rTg4510 (TR) and wildtype (WT)
mice were imaged
in-vivo (WT=10, TR=10)
and
ex-vivo (WT=8, TR=8) at 7.5
months. Mice were secured in a cradle
under anaesthesia with 1-2% isoflurane in 100% oxygen for
in-vivo imaging which was followed by perfuse fixation (0.9% saline
(15–20mL) followed by 50mL 10% buffered formalin). Brains were removed and stored in-skull at 4
oC
in buffered formalin. Prior to
ex-vivo imaging, each brain was
rehydrated in PBS (3 weeks) and transferred to a 20mL syringe filled with a
fomblin perfluoropolyether (Solvay Solexis SpA., Italy). Data were acquired at 9.4T using a 72mm
birdcage coil for transmission. Signal was detected using a two-channel array
head coil (
in-vivo) and a 26mm
birdcage coil (
ex-vivo) (RAPID, Germany). Pulse sequence parameters are listed in
Figure 1. Phase images were unwrapped using laplacian (
in-vivo) and path-based (
ex-vivo)
methods, and background contributions
were removed using VSHARP[5] (minimum kernel
width = 0.6mm). QSMs were generated by
TKD (t=5) corrected for underestimation[6]. A fully automated software pipeline was used
to register magnitude data and generate brain masks. ROIs were manually drawn on the atlas image (Fig.2)
and back propagated onto individual
QSM/T2*maps to calculate mean parameter values.
Group comparisons were made using two-tailed t-tests (p<0.05).
Results
Differences in magnetic susceptibility and T2* in rTg4510s relative to
WT controls were most significant in the striatum which appears hyperintense in
the mean QSMs (Fig.3a,b). In both the
in-vivo, and
ex-vivo datasets, an increased paramagnetic susceptibility and
reduced T2* was calculated for the rTg4510 (Fig.3c,d). In the hippocampus, a significant increase in
magnetic susceptibility was also observed in both
in-vivo and
ex-vivo data (Fig.4a),
with no differences in T2*. A shortening
of T2* in the cortex was observed in the
in-vivo
data only. The
ex-vivo measurements of susceptibility were elevated in the rTg4510
thalamus with a reduced T2*, findings that were not replicated
in-vivo where magnetic susceptibility
was found to be decreased with no change in T2*. An increased magnetic
susceptibility (with no difference in T2*) was detected the corpus callosum of
the rTg4510 mice in both
in-vivo and
ex-vivo datasets (Fig.4b). In mean
parameter maps, a loss in white-grey matter contrast in the rostral corpus
callosum of the rTg4510 is evident in the QSM data only (Fig.5).
Discussion
The basal ganglia contains structures that are known to be iron rich
relative to the rest of the brain and are particularly vulnerable to
pathological iron accumulation in AD[1]. The
striatum, a constituent part of this system, was found to have increased
magnetic susceptibility in the rTg4510.
Reductions in T2*, a more established method of
in-vivo iron mapping[4], supported this finding. These T2* and QSM results are in good
agreement with clinical studies of AD[2] and suggest that iron deposition in the
striatum may be related to tangle pathology.
QSM values in the hippocampus, a region previously shown to exhibit iron
accumulation in AD[7], were also more paramagnetic in the rTg4510
relative to controls. Iron has
previously been detected in oligodendrocytes and dystrophic myelinated axons in
AD[7] and may be responsible for the magnetic
susceptibility increases in the corpus callosum of the rTg4510 mice. However, abnormalities in the myelination have
been observed in AD[2], and these susceptibility changes may also be
caused by reduced myelin content, known to be diamagnetic. Work is ongoing to verify the source of the observed
magnetic susceptibility differences through histopathological analysis of the
ex-vivo tissue.
Acknowledgements
No acknowledgement found.References
1. Bartzokis G, Tishler
TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in
Alzheimer's and Huntingon's disease. Cellular and molecular biology
(Noisy-le-Grand, France) 2000;46(4):821-833.
2. Acosta-Cabronero J,
Williams GB, Cardenas-Blanco A, et al.
In Vivo Quantitative Susceptibility Mapping (QSM)
in Alzheimer's Disease. PLoS ONE 2013;8(11):e81093.
3. Ward RJ, Zucca FA, Duyn
JH, et al. The role of iron in brain ageing and
neurodegenerative disorders. The Lancet Neurology 2014;13(10):1045-1060.
4. Langkammer C, Ropele S,
Pirpamer L, et al. MRI for Iron Mapping in Alzheimer's Disease.
Neurodegenerative Diseases 2014;13(2-3):189-191.
5. Schweser F, Deistung A,
Lehr BW, et al. Quantitative imaging of intrinsic magnetic tissue
properties using MRI signal phase: An approach to in vivo brain iron
metabolism? NeuroImage 2011;54(4):2789-2807.
6. Schweser F, Deistung A,
Sommer K, et al. Toward online reconstruction of quantitative
susceptibility maps: Superfast dipole inversion. Magnetic Resonance in Medicine
2013;69(6):1581-1593.
7. Quintana C, Gutiérrez
L. Could a dysfunction of ferritin be a determinant factor in the aetiology of
some neurodegenerative diseases? Biochimica et Biophysica Acta (BBA) - General
Subjects 2010;1800(8):770-782.